Form 4: TriSalus Life Sciences Director Gary B. Gordon Granted 15,000 Stock Options

TriSalus Life Sciences, Inc. Director Gary B. Gordon was granted 15,000 stock options with an exercise price of $5.50, set to vest over one year or by the next annual stockholder meeting.

Summary

• Gary B. Gordon, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options.
• The options have an exercise price of $5.50 per share.
• The grant date for these options was June 12, 2025.
• The options are set to expire on June 11, 2035.
• The shares subject to the option will fully vest on the one-year anniversary of the grant date (June 12, 2025), or earlier, on the date of the Issuer's next annual stockholder meeting, contingent on Mr. Gordon's continued service.
• Following this transaction, Mr. Gordon beneficially owns 56,250 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders, which is generally a neutral to slightly positive signal. It does not indicate any significant operational or financial changes.

Positives

• The grant of stock options to Director Gary B. Gordon aligns his interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Risks

• The value of the stock options is subject to the future performance of TriSalus Life Sciences, Inc.'s common stock. If the stock price does not exceed the exercise price of $5.50, the options may not hold value.
• Vesting of the options is contingent on the reporting person's continued service with the Issuer.

Future Outlook

The vesting schedule indicates a future milestone for the options, with full vesting expected by June 12, 2026, or earlier, tied to the company's next annual stockholder meeting and the director's continued service.

Industry Context

This Form 4 filing reflects a common practice in the biotechnology and life sciences industry where equity-based compensation, such as stock options, is used to attract, retain, and incentivize directors and key personnel, aligning their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance.

Next Steps

• The shares subject to the option will fully vest on the one-year anniversary of the grant date (June 12, 2025), which is June 12, 2026.
• Alternatively, the shares will fully vest on the date of the Issuer's next annual stockholder meeting, whichever comes first, subject to continued service.

Key Dates

Recommendation

Keywords

TriSalus Life Sciences, TLSI, SEC Form 4, stock options, insider transaction, director compensation, equity grant, beneficial ownership